1
|
Tahmasvand R, Dehghani S, Kooshafar Z, Emami Najafi SA, Almasirad A, Salimi M. In vitro and in vivo activity of a novel oxamide-hydrazone hybrid derivative against triple-negative breast cancer. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:5119-5129. [PMID: 38240779 DOI: 10.1007/s00210-023-02931-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 12/25/2023] [Indexed: 06/12/2024]
Abstract
Triple-negative breast cancer is a subtype of breast cancer with poor clinical outcome, and currently, no effective targeted therapies are available. Since cancer develops owing to deregulation of apoptosis, employing therapeutic strategies with the ability to target the molecules involved in apoptosis induction would provide a valid approach to hinder tumor progression. Hydrazide-hydrazones and oxamide molecules are the subject of intense studies due to their anticancer effects via apoptosis induction. In the present study, we attempted to elucidate the mechanism of action of a synthesized compound (compound A) in inducing cell death. Annexin/PI and Western blotting analyses, DAPI staining, mitochondrial membrane potential probe, and flow cytometry were applied for the in vitro evaluations. 4T1 syngeneic mouse model and immunohistochemistry were used for the in vivo assessments. Compound A caused cell death by inducing apoptosis in MDA-MB-231 cells in a mitochondrial-dependent manner at high concentrations after 72 h of incubation. Compound A also impeded tumor growth in a 4T1 syngeneic mouse model as evidenced by hematoxylin and eosin staining of the tumors. Furthermore, it significantly diminished the expression of pro-caspase-3, Ki67, and CD31 markers in the tumor sections. Conclusively, this study for the first time reports the anti-cancer efficacy of compound A in both in vitro and in vivo models and its potential in the treatment of triple-negative breast cancer.
Collapse
Affiliation(s)
- Raheleh Tahmasvand
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
| | - Soudeh Dehghani
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
| | - Zahra Kooshafar
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran
| | - Seyedeh Azadeh Emami Najafi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Ali Almasirad
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
| | - Mona Salimi
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, Iran.
| |
Collapse
|
2
|
Chagas C, Mansano JV, da Silva EB, Petri G, da Costa Aguiar Alves Reis B, Schumacher ML, Haddad PS, Pereira EC, Britos TN, Barreiro EJ, Lima LM, Ferreira FF, Fonseca FLA. In vitro results with minimal blood toxicity of a combretastatin A4 analogue. Invest New Drugs 2024; 42:318-325. [PMID: 38758478 DOI: 10.1007/s10637-024-01440-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Accepted: 04/26/2024] [Indexed: 05/18/2024]
Abstract
Cancer is a disease caused by uncontrolled cell growth that is responsible for several deaths worldwide. Breast cancer is the most common type of cancer among women and is the leading cause of death. Chemotherapy is the most commonly used treatment for cancer; however, it often causes various side effects in patients. In this study, we evaluate the antineoplastic activity of a parent compound based on a combretastatin A4 analogue. We test the compound at 0.01 mg mL- 1, 0.1 mg mL- 1, 1.0 mg mL- 1, 10.0 mg mL- 1, 100.0 mg mL- 1, and 1,000.0 mg mL- 1. To assess molecular antineoplastic activity, we conduct in vitro tests to determine the viability of Ehrlich cells and the blood mononuclear fraction. We also analyze the cytotoxic behavior of the compound in the blood and blood smear. The results show that the molecule has a promising antineoplastic effect and crucial anticarcinogenic action. The toxicity of blood cells does not show statistically significant changes.
Collapse
Affiliation(s)
- Camila Chagas
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil.
| | - Jaqueline Vital Mansano
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
| | - Emerson Barbosa da Silva
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
| | - Giuliana Petri
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
| | - Beatriz da Costa Aguiar Alves Reis
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
| | - Maria Lúcia Schumacher
- Chemistry Department, Federal University of São Paulo, Campus Diadema, Rua São Nicolau, 210, Centro, 09913-030, Diadema, SP, Brazil
| | - Paula Silvia Haddad
- Chemistry Department, Federal University of São Paulo, Campus Diadema, Rua São Nicolau, 210, Centro, 09913-030, Diadema, SP, Brazil
| | - Edimar Cristiano Pereira
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
| | - Tatiane Nassar Britos
- Chemistry Department, Federal University of São Paulo, Campus Diadema, Rua São Nicolau, 210, Centro, 09913-030, Diadema, SP, Brazil
| | - Eliezer J Barreiro
- LASSBio, Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Av. Carlos Chagas, 373 - bloco K, 2º andar, sala 35 - Prédio do Centro de Ciências da Saúde, Cidade Universitária, Ilha do Fundão, 21941-902, Rio de Janeiro, RJ, Brazil
- Graduate Program of Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ), Av. Athos da Silveira Ramos, nº 149, Bloco A- 7º andar, Centro de Tecnologia, Cidade Universitária, 21941-909, Rio de Janeiro, RJ, Brazil
| | - Lídia Moreira Lima
- LASSBio, Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Av. Carlos Chagas, 373 - bloco K, 2º andar, sala 35 - Prédio do Centro de Ciências da Saúde, Cidade Universitária, Ilha do Fundão, 21941-902, Rio de Janeiro, RJ, Brazil
- Graduate Program of Chemistry, Institute of Chemistry, Federal University of Rio de Janeiro (UFRJ), Av. Athos da Silveira Ramos, nº 149, Bloco A- 7º andar, Centro de Tecnologia, Cidade Universitária, 21941-909, Rio de Janeiro, RJ, Brazil
| | - Fabio Furlan Ferreira
- Center for Natural and Human Sciences (CCNH), Federal University of ABC (UFABC), 09280- 560, Santo André, SP, Brazil.
- Nanomedicine Research Unit (NANOMED), Federal University of ABC (UFABC), 09280-560, Santo André, SP, Brazil.
| | - Fernando Luiz Affonso Fonseca
- Clinical Analysis Laboratory of the Centro Universitário FMABC, Av. Príncipe de Gales, 821, Bairro Vila Príncipe de Gales, 09060-650, Santo André, SP, Brazil
- Chemistry Department, Federal University of São Paulo, Campus Diadema, Rua São Nicolau, 210, Centro, 09913-030, Diadema, SP, Brazil
| |
Collapse
|
3
|
Vlad IM, Nuță DC, Căproiu MT, Dumitrașcu F, Kapronczai E, Mük GR, Avram S, Niculescu AG, Zarafu I, Ciorobescu VA, Brezeanu AM, Limban C. Synthesis and Characterization of New N-acyl Hydrazone Derivatives of Carprofen as Potential Tuberculostatic Agents. Antibiotics (Basel) 2024; 13:212. [PMID: 38534647 DOI: 10.3390/antibiotics13030212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 02/09/2024] [Accepted: 02/20/2024] [Indexed: 03/28/2024] Open
Abstract
N-acyl hydrazone (NAH) is recognized as a promising framework in drug design due to its versatility, straightforward synthesis, and attractive range of biological activities, including antimicrobial, antitumoral, analgesic, and anti-inflammatory properties. In the global context of increasing resistance of pathogenic bacteria to antibiotics, NAHs represent potential solutions for developing improved treatment alternatives. Therefore, this research introduces six novel derivatives of (EZ)-N'-benzylidene-2-(6-chloro-9H-carbazol-2-yl)propanehydrazide, synthesized using a microwave-assisted method. In more detail, we joined two pharmacophore fragments in a single molecule, represented by an NSAID-type carprofen structure and a hydrazone-type structure, obtaining a new series of NSAID-N-acyl hydrazone derivatives that were further characterized spectrally using FT-IR, NMR, and HRMS investigations. Additionally, the substances were assessed for their tuberculostatic activity by examining their impact on four strains of M. tuberculosis, including two susceptible to rifampicin (RIF) and isoniazid (INH), one susceptible to RIF and resistant to INH, and one resistant to both RIF and INH. The results of our research highlight the potential of the prepared compounds in fighting against antibiotic-resistant M. tuberculosis strains.
Collapse
Affiliation(s)
- Ilinca Margareta Vlad
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia no. 6, 020956 Bucharest, Romania
| | - Diana Camelia Nuță
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia no. 6, 020956 Bucharest, Romania
| | - Miron Theodor Căproiu
- "C. D. Nenitzescu" Institute of Organic and Supramolecular Chemistry, 202B Splaiul Independenței, 060023 Bucharest, Romania
| | - Florea Dumitrașcu
- "C. D. Nenitzescu" Institute of Organic and Supramolecular Chemistry, 202B Splaiul Independenței, 060023 Bucharest, Romania
| | - Eleonóra Kapronczai
- Department of Chemistry, Supramolecular Organic and Organometallic Chemistry Centre, Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 11 Arany János, 400028 Cluj-Napoca, Romania
| | - Georgiana Ramona Mük
- Faculty of Biology, University of Bucharest, Splaiul Independenței 91-95, 050095 Bucharest, Romania
- "St. Stephen's" Pneumoftiziology Hospital, Șos. Ștefan cel Mare 11, 020122 Bucharest, Romania
| | - Speranta Avram
- Faculty of Biology, University of Bucharest, Splaiul Independenței 91-95, 050095 Bucharest, Romania
| | - Adelina Gabriela Niculescu
- Research Institute of the University of Bucharest, Sos. Panduri 90-92, 050095 Bucharest, Romania
- Department of Science and Engineering of Oxide Materials and Nanomaterials, National University of Science and Technology Politehnica Bucharest, 011061 Bucharest, Romania
| | - Irina Zarafu
- Department of Organic Chemistry, Biochemistry and Catalysis, Faculty of Chemistry, University of Bucharest, 4-12 Regina Elisabeta, 030018 Bucharest, Romania
| | - Vanesa Alexandra Ciorobescu
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia no. 6, 020956 Bucharest, Romania
| | - Ana Maria Brezeanu
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia no. 6, 020956 Bucharest, Romania
| | - Carmen Limban
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia no. 6, 020956 Bucharest, Romania
| |
Collapse
|
4
|
Kassab AE. N-Acylhydrazone Pharmacophore's Analgesic and Anti-inflammatory Profile: Recent Advancements during the Past Ten Years. Curr Pharm Des 2024; 30:333-351. [PMID: 38303528 DOI: 10.2174/0113816128282470240117072322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 12/30/2023] [Accepted: 01/05/2024] [Indexed: 02/03/2024]
Abstract
Due to its important biological and pharmacological properties, in the field of medicinal chemistry and drug discovery, the N-acylhydrazone motif has shown to be extremely adaptable and promising. This scaffold has become a crucial component in the synthesis of numerous bioactive agents. N-Acylhydrazones are also interesting biological and synthetic tools due to their easy and straightforward synthesis. The current review provides a summary of the analgesic and anti-inflammatory activities of N-acylhydrazone derivatives over the past ten years. A brief discussion of structure-activity relationships is also provided which may guide researchers in medicinal chemistry to develop derivatives based on N-acylhydrazone scaffold as potent anti-inflammatory candidates.
Collapse
Affiliation(s)
- Asmaa E Kassab
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt
| |
Collapse
|
5
|
Guimarães CDJ, Carneiro TR, Frederico MJS, de Carvalho GGC, Little M, Freire VN, França VLB, do Amaral DN, Guedes JDS, Barreiro EJ, Lima LM, Barros-Nepomuceno FWA, Pessoa C. Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent. Pharmaceutics 2023; 15:pharmaceutics15041282. [PMID: 37111767 PMCID: PMC10144566 DOI: 10.3390/pharmaceutics15041282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Revised: 03/30/2023] [Accepted: 04/14/2023] [Indexed: 04/29/2023] Open
Abstract
LASSBio-1920 was synthesized due to the poor solubility of its natural precursor, combretastatin A4 (CA4). The cytotoxic potential of the compound against human colorectal cancer cells (HCT-116) and non-small cell lung cancer cells (PC-9) was evaluated, yielding IC50 values of 0.06 and 0.07 μM, respectively. Its mechanism of action was analyzed by microscopy and flow cytometry, where LASSBio-1920 was found to induce apoptosis. Molecular docking simulations and the enzymatic inhibition study with wild-type (wt) EGFR indicated enzyme-substrate interactions similar to other tyrosine kinase inhibitors. We suggest that LASSBio-1920 is metabolized by O-demethylation and NADPH generation. LASSBio-1920 demonstrated excellent absorption in the gastrointestinal tract and high central nervous system (CNS) permeability. The pharmacokinetic parameters obtained by predictions indicated that the compound presents zero-order kinetics and, in a human module simulation, accumulates in the liver, heart, gut, and spleen. The pharmacokinetic parameters obtained will serve as the basis to initiate in vivo studies regarding LASSBio-1920's antitumor potential.
Collapse
Affiliation(s)
- Celina de Jesus Guimarães
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
- Pharmacy Sector, Oncology Control Foundation of the State of Amazonas (FCECON), Manaus 69040-010, AM, Brazil
| | - Teiliane Rodrigues Carneiro
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
| | - Marisa Jadna Silva Frederico
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
| | - Guilherme G C de Carvalho
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
| | - Matthew Little
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
| | - Valder N Freire
- Department of Physics, Federal University of Ceara (UFC), Fortaleza 60440-900, CE, Brazil
| | - Victor L B França
- Department of Physics, Federal University of Ceara (UFC), Fortaleza 60440-900, CE, Brazil
| | - Daniel Nascimento do Amaral
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-590, RJ, Brazil
| | - Jéssica de Siqueira Guedes
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-590, RJ, Brazil
| | - Eliezer J Barreiro
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-590, RJ, Brazil
| | - Lídia Moreira Lima
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-590, RJ, Brazil
| | - Francisco W A Barros-Nepomuceno
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
- Institute of Health Sciences, University for International Integration of the Afro-Brazilian Lusophony, Redenção 62790-000, CE, Brazil
| | - Claudia Pessoa
- Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceara (UFC), Fortaleza 60430-275, CE, Brazil
| |
Collapse
|
6
|
Design, synthesis, characterization, antioxidant, antiproliferative activity and molecular docking studies of new transition metal complexes of 1,2,4-triazole as combretastatin A-4 analogues. J Mol Struct 2023. [DOI: 10.1016/j.molstruc.2022.134437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Kassab AE. Anticancer agents incorporating the N-acylhydrazone scaffold: Progress from 2017 to present. Arch Pharm (Weinheim) 2023; 356:e2200548. [PMID: 36638264 DOI: 10.1002/ardp.202200548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/20/2022] [Accepted: 12/23/2022] [Indexed: 01/15/2023]
Abstract
The N-acylhydrazone motif has been shown to be particularly adaptable and promising in the area of medicinal chemistry and drug development, due to its significant biological and pharmacological characteristics. Moreover, N-acylhydrazones are appealing synthetic and biological tools because of their simple and straightforward synthesis. This scaffold has emerged as a fundamental building block for the synthesis of bioactive compounds. Particularly, the N-acylhydrazone scaffold served as a base for the synthesis of a number of potent anticancer agents acting via different mechanisms. An updated summary of the anticancer activity of N-acylhydrazone derivatives described in the literature (from 2017 to 2022) is provided in the current review. It discusses the structure-activity relationship (SAR) of N-acylhydrazone derivatives exhibiting anticancer potential, which could be helpful in designing and developing new derivatives as effective antiproliferative candidates in the future.
Collapse
Affiliation(s)
- Asmaa E Kassab
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| |
Collapse
|
8
|
Dehbid M, Tahmasvand R, Tasharofi M, Shojaie F, Aghamaali M, Almasirad A, Salimi M. Synthesis of oxamide-hydrazone hybrid derivatives as potential anticancer agents. Res Pharm Sci 2022; 18:24-38. [PMID: 36846733 PMCID: PMC9951783 DOI: 10.4103/1735-5362.363593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2022] [Revised: 09/04/2022] [Accepted: 09/11/2022] [Indexed: 12/25/2022] Open
Abstract
Background and purpose Considering various studies implying anticancer activity of the hydrazone and oxamide derivatives through different mechanisms such as kinases and calpain inhibition, herein, we report the synthesis, characterization, and evaluation of the antiproliferative effect of a series of hydrazones bearing oxamide moiety compounds (7a-7n) against a panel of cancer cell lines to explore a novel and promising anticancer agent (7k). Experimental approach Chemical structures of the synthesized compounds were confirmed by FTIR, 1H-NMR, 13C-NMR, and mass spectra. The antiproliferative activity and cell cycle progression of the target compound were investigated using the MTT assay and flow cytometry. Findings/Results Compound 7k with 2-hydroxybenzylidene structure was found to have a significant in vitro anti-proliferative influence on MDA-MB-231 (human adenocarcinoma breast cancer) and 4T1 (mouse mammary tumor) cells as the model of triple-negative breast cancer, with the IC50-72h values of 7.73 ± 1.05 and 1.82 ± 1.14 μM, respectively. Following 72-h incubation with compound 7k, it caused MDA-MB-231 cell death through G1/S cell cycle arrest at high concentrations (12 and 16 μM). Conclusion and implications Conclusively, this study for the first time reports the anti-proliferative efficacy of compound 7k possessing 2-hydroxyphenyl moiety, which may serve as a potent candidate in triple-negative breast cancer treatment.
Collapse
Affiliation(s)
- Mina Dehbid
- Department of Biology, Faculty of Science, University of Guilan, Rasht, I.R. Iran
| | - Raheleh Tahmasvand
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, I.R. Iran
| | - Marzieh Tasharofi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, I.R. Iran
| | - Fatemeh Shojaie
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, I.R. Iran
| | | | - Ali Almasirad
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, I.R. Iran,Corresponding authors: A. Almasirad, Tel: +98-2122640051, Fax: +98-22602059
M. Salimi, Tel: +98-2164112264, Fax: +98-2164112834
| | - Mona Salimi
- Department of Physiology and Pharmacology, Pasteur Institute of Iran, Tehran, I.R. Iran,Corresponding authors: A. Almasirad, Tel: +98-2122640051, Fax: +98-22602059
M. Salimi, Tel: +98-2164112264, Fax: +98-2164112834
| |
Collapse
|
9
|
Yeye EO, Adeniyi-Akee MA, Ahmed SA, Aboaba SA. In Silico studies and Antimicrobial Investigation of Synthesised Novel N-acylhydrazone Derivatives of Indole. SCIENTIFIC AFRICAN 2022. [DOI: 10.1016/j.sciaf.2022.e01463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
10
|
Koopaei NN, Shademani M, Yazdi NS, Tahmasvand R, Dehbid M, Koopaei MN, Azizian H, Mousavi Z, Almasirad A, Salimi M. Design and synthesis of novel ureido and thioureido conjugated hydrazone derivatives with potent anticancer activity. BMC Chem 2022; 16:81. [PMID: 36320042 PMCID: PMC9624014 DOI: 10.1186/s13065-022-00873-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 10/04/2022] [Indexed: 11/05/2022] Open
Abstract
Background Compounds possessing urea/thiourea moiety have a wide range of biological properties including anticancer activity. On the other hand, taking advantage of the low toxicity and structural diversity of hydrazone derivatives, they are presently being considered for designing chemical compounds with hydrazone moiety in the field of cancer treatment. With this in mind, a series of novel ureido/thioureido derivatives possessing a hydrazone moiety bearing nitro and chloro substituents (4a–4i) have been designed, synthesized, characterized and evaluated for their in vitro cytotoxic effect on HT-29 human colon carcinoma and HepG2 hepatocarcinoma cell lines. Results Two compounds (4c and 4e) having the chloro phenylurea group hybridized with phenyl hydrazone bearing nitro or chloro moieties demonstrated potent anticancer effect with the IC50 values between 2.2 and 4.8 µM at 72 h. The mechanism of action of compound 4c was revealed in hepatocellular carcinoma cells as an inducer of apoptosis in a caspase-independent pathway. Conclusion Taken together, the current work presented compound 4c as a potential lead compound in developing future hepatocellular carcinoma chemotherapy drugs. Methods The compounds were synthesized and then characterized by physical and spectral data (FT-IR, 1H-NMR, 13C-NMR, Mass). The anticancer activity was assessed using MTT assay, flowcytometry, annexin-V, DAPI staining and Western blot analysis. Graphical Abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1186/s13065-022-00873-3.
Collapse
Affiliation(s)
- Nasrin Nassiri Koopaei
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran
| | - Mehrasa Shademani
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran ,grid.411463.50000 0001 0706 2472Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Nasrin Shirzad Yazdi
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran ,grid.412571.40000 0000 8819 4698Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Raheleh Tahmasvand
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran
| | - Mina Dehbid
- grid.411872.90000 0001 2087 2250Department of Biology, Faculty of Science, University of Guilan, Rasht, Iran
| | - Mansur Nassiri Koopaei
- grid.411705.60000 0001 0166 0922Department of Medicinal Chemistry, Faculty of Pharmacy and Drug Design & Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Homa Azizian
- grid.411746.10000 0004 4911 7066Department of Medicinal Chemistry, School of Pharmacy-International Campus, Iran University of Medical Science, Tehran, Iran
| | - Zahra Mousavi
- grid.411463.50000 0001 0706 2472Department of Pharmacology & Toxicology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
| | - Ali Almasirad
- grid.411463.50000 0001 0706 2472Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, P.O. Box 1941933111, Tehran, Iran
| | - Mona Salimi
- grid.420169.80000 0000 9562 2611Department of Physiology and Pharmacology, Pasteur Institute of Iran, P.O. Box 1316943551, Tehran, Iran
| |
Collapse
|
11
|
Biological evaluation of imidazopyridine derivatives as potential anticancer agents against breast cancer cells. Med Chem Res 2022. [DOI: 10.1007/s00044-022-02984-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
12
|
Kausar N, Murtaza S, Khalid M, Shoukat U, Asad M, Arshad MN, Asiri AM, Braga AA. Experimental and Quantum Chemical Approaches for Hydrazide-based Crystalline Organic Chromophores: Synthesis, SC-XRD, Spectroscopic and Nonlinear Optical Properties. J Mol Struct 2022. [DOI: 10.1016/j.molstruc.2022.134208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
13
|
Ozadali-Sari K, Ceylan S, Yucel ES, Sabuncuoglu S, Unsal-Tan O. Design, Synthesis and Cytotoxic Evaluation of N‐acylhydrazone‐Incorporated Isoxazolo[4,5‐d]pyridazin‐4(5H)‐one Derivatives. Chem Biodivers 2022; 19:e202200389. [DOI: 10.1002/cbdv.202200389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 08/19/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Keriman Ozadali-Sari
- Hacettepe Universitesi Eczacilik Fakultesi Pharmaceutical chemistry Department of Pharmaceutical Chemistry, Hacettepe UniversityFaculty of Pharmacy, Ankara 06100 06100 Ankara TURKEY
| | - Serenay Ceylan
- Hacettepe Universitesi Eczacilik Fakultesi Pharmaceutical Chemistry 1Department of Pharmaceutical Chemistry, Hacettepe UniversityFaculty of PharmacyAnkara 06100, Turkey 06100 Ankara TURKEY
| | - Evnur Sinem Yucel
- Hacettepe Universitesi Eczacilik Fakultesi Pharmaceutical Chemistry Department of Pharmaceutical Chemistry, Hacettepe University,Faculty of Pharmacy 06100 Ankara TURKEY
| | - Suna Sabuncuoglu
- Hacettepe Universitesi Eczacilik Fakultesi Pharmaceutical Toxicology Department of Pharmaceutical Toxicology, Hacettepe University,Faculty of Pharmacy, Ankara 06100 06100 Ankara TURKEY
| | - Oya Unsal-Tan
- Hacettepe Universitesi Eczacilik Fakultesi Department of Pharmaceutical Chemistry, Hacettepe University, Faculty of Pharmacy, Ankara 06100 06100 Ankara TURKEY
| |
Collapse
|
14
|
Barbosa G, Gelves LGV, Costa CMX, Franco LS, de Lima JAL, Aparecida-Silva C, Teixeira JD, Mermelstein CDS, Barreiro EJ, Lima LM. Discovery of Putative Dual Inhibitor of Tubulin and EGFR by Phenotypic Approach on LASSBio-1586 Homologs. Pharmaceuticals (Basel) 2022; 15:ph15080913. [PMID: 35893736 PMCID: PMC9394307 DOI: 10.3390/ph15080913] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 07/18/2022] [Accepted: 07/19/2022] [Indexed: 01/25/2023] Open
Abstract
Combretastatin A-4 (CA-4, 1) is an antimicrotubule agent used as a prototype for the design of several synthetic analogues with anti-tubulin activity, such as LASSBio-1586 (2). A series of branched and unbranched homologs of the lead-compound 2, and vinyl, ethinyl and benzyl analogues, were designed and synthesized. A comparison between the cytotoxic effect of these homologs and 2 on different human tumor cell lines was performed from a cell viability study using MTT with 48 h and 72 h incubations. In general, the compounds were less potent than CA-4, showing CC50 values ranging from 0.030 μM to 7.53 μM (MTT at 72 h) and 0.096 μM to 8.768 μM (MTT at 48 h). The antimitotic effect of the target compounds was demonstrated by cell cycle analysis through flow cytometry, and the cellular mechanism of cytotoxicity was determined by immunofluorescence. While the benzyl homolog 10 (LASSBio-2070) was shown to be a microtubule stabilizer, the lead-compound 2 (LASSBio-1586) and the methylated homolog 3 (LASSBio-1735) had microtubule destabilizing behavior. Molecular docking studies were performed on tubulin protein to investigate their binding mode on colchicine and taxane domain. Surprisingly, the benzyl homolog 10 was able to modulate EGFR phosphorylate activity in a phenotypic model. These data suggest LASSBio-2070 (10) as a putative dual inhibitor of tubulin and EGFR. Its binding mode with EGFR was determined by molecular docking and may be useful in lead-optimization initiatives.
Collapse
Affiliation(s)
- Gisele Barbosa
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - Luis Gabriel Valdivieso Gelves
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - Caroline Marques Xavier Costa
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - Lucas Silva Franco
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - João Alberto Lins de Lima
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - Cristiane Aparecida-Silva
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - John Douglas Teixeira
- Laboratório de Diferenciação Muscular e Citoesqueleto, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (J.D.T.); (C.d.S.M.)
| | - Claudia dos Santos Mermelstein
- Laboratório de Diferenciação Muscular e Citoesqueleto, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (J.D.T.); (C.d.S.M.)
| | - Eliezer J. Barreiro
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
| | - Lidia Moreira Lima
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil; (G.B.); (L.G.V.G.); (C.M.X.C.); (L.S.F.); (J.A.L.d.L.); (C.A.-S.); (E.J.B.)
- Programa de Pós-graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil
- Correspondence:
| |
Collapse
|
15
|
Oliveira FA, Pinto ACS, Duarte CL, Taranto AG, Lorenzato Junior E, Cordeiro CF, Carvalho DT, Varotti FP, Fonseca AL. Evaluation of antiplasmodial activity in silico and in vitro of N-acylhydrazone derivatives. BMC Chem 2022; 16:50. [PMID: 35810303 PMCID: PMC9271247 DOI: 10.1186/s13065-022-00843-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 06/17/2022] [Indexed: 11/21/2022] Open
Abstract
N-acylhydrazones are considered privileged structures in medicinal chemistry, being part of antimicrobial compounds (for example). In this study we show the activity of N-acylhydrazone compounds, namely AH1, AH2, AH4, AH5 in in vitro tests against the chloroquine-resistant strain of Plasmodium falciparum (W2) and against WI26 VA-4 human cell lines. All compounds showed low cytotoxicity (LC50 > 100 µM). The AH5 compound was the most active against Plasmodium falciparum, with an IC50 value of 0.07 μM. AH4 and AH5 were selected among the tested compounds for molecular docking calculations to elucidate possible targets involved in their mechanism of action and the SwissADME analysis to predict their pharmacokinetic profile. The AH5 compound showed affinity for 12 targets with low selectivity, while the AH4 compound had greater affinity for only one target (3PHC). These compounds met Lipinski's standards in the ADME in silico tests, indicating good bioavailability results. These results demonstrate that these N-acylhydrazone compounds are good candidates for future preclinical studies against malaria.
Collapse
Affiliation(s)
- Fernanda A Oliveira
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil
| | - Ana Claudia S Pinto
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil.
| | - Caique L Duarte
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil
| | - Alex G Taranto
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil
| | - Eder Lorenzato Junior
- Laboratório de Pesquisa Em Química Farmacêutica, Universidade Federal de Alfenas, Campus Alfenas, Alfenas, MG, 37130-001, Brazil
| | - Cleydson Finotti Cordeiro
- Laboratório de Pesquisa Em Química Farmacêutica, Universidade Federal de Alfenas, Campus Alfenas, Alfenas, MG, 37130-001, Brazil
| | - Diogo T Carvalho
- Laboratório de Pesquisa Em Química Farmacêutica, Universidade Federal de Alfenas, Campus Alfenas, Alfenas, MG, 37130-001, Brazil
| | - Fernando P Varotti
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil
| | - Amanda L Fonseca
- Núcleo de Pesquisa Em Química Biológica (NQBio), Universidade Federal de São João Del Rei, Campus Centro Oeste, Divinópolis, MG, 35501-296, Brazil.
| |
Collapse
|
16
|
Achi PA, Coulibali S, Molou KYG, Coulibaly S, Kouassi S, Sissouma D, Ouattara L, Ané A. Stereochemical design and conformation determinations of new benzimidazole-N-acylhydrazone derivatives. SYNTHETIC COMMUN 2022. [DOI: 10.1080/00397911.2022.2084417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Patrick-Armand Achi
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Siomenan Coulibali
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Kouassi Yves Guillaume Molou
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Souleymane Coulibaly
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Signo Kouassi
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Drissa Sissouma
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Lassiné Ouattara
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| | - Adjou Ané
- Laboratoire de Constitution et Réaction de la Matière, UFR Sciences des Structures de la Matière et Technologie, Université Félix Houphouët Boigny, Abidjan, Côte d’Ivoire
| |
Collapse
|
17
|
The Current Directions of Searching for Antiparasitic Drugs. Molecules 2022; 27:molecules27051534. [PMID: 35268635 PMCID: PMC8912034 DOI: 10.3390/molecules27051534] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 02/18/2022] [Accepted: 02/22/2022] [Indexed: 12/02/2022] Open
Abstract
Parasitic diseases are still a huge problem for mankind. They are becoming the main cause of chronic diseases in the world. Migration of the population, pollution of the natural environment, and climate changes cause the rapid spread of diseases. Additionally, a growing resistance of parasites to drugs is observed. Many research groups are looking for effective antiparasitic drugs with low side effects. In this work, we present the current trends in the search for antiparasitic drugs. We report known drugs used in other disease entities with proven antiparasitic activity and research on new chemical structures that may be potential drugs in parasitic diseases. The described investigations of antiparasitic compounds can be helpful for further drug development.
Collapse
|
18
|
Şenkardeş S, Erdoğan Ö, Çevik Ö, Küçükgüzel ŞG. Synthesis and biological evaluation of novel aryloxyacetic acid hydrazide derivatives as anticancer agents. SYNTHETIC COMMUN 2021. [DOI: 10.1080/00397911.2021.1945105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Sevil Şenkardeş
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başıbüyük, İstanbul, Turkey
| | - Ömer Erdoğan
- Department of Biochemistry, School of Medicine, Aydın Adnan Menderes University, Efeler, Aydın, Turkey
| | - Özge Çevik
- Department of Biochemistry, School of Medicine, Aydın Adnan Menderes University, Efeler, Aydın, Turkey
| | - Ş. Güniz Küçükgüzel
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Başıbüyük, İstanbul, Turkey
| |
Collapse
|
19
|
Perużyńska M, Borzyszkowska-Ledwig A, Sośnicki JG, Struk Ł, Idzik TJ, Maciejewska G, Skalski Ł, Piotrowska K, Łukasik P, Droździk M, Kurzawski M. Synthesis and Anticancer Activity of Mitotic-Specific 3,4-Dihydropyridine-2(1 H)-thiones. Int J Mol Sci 2021; 22:2462. [PMID: 33671106 PMCID: PMC7957618 DOI: 10.3390/ijms22052462] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 02/24/2021] [Accepted: 02/25/2021] [Indexed: 01/21/2023] Open
Abstract
Most anticancer drugs target mitosis as the most crucial and fragile period of rapidly dividing cancer cells. However the limitations of classical chemotherapeutics drive the search for new more effective and selective compounds. For this purpose structural modifications of the previously characterized pyridine aalog (S1) were incorporated aiming to obtain an antimitotic inhibitor of satisfactory and specific anticancer activity. Structure-activity relationship analysis of the compounds against a panel of cancer cell lines allowed to select a compound with a thiophene ring at C5 of a 3,4-dihydropyridine-2(1H)-thione (S22) with promising antiproliferative activity (IC50 equal 1.71 ± 0.58 µM) and selectivity (SI = 21.09) against melanoma A375 cells. Moreover, all three of the most active compounds from the antiproliferative study, namely S1, S19 and S22 showed better selectivity against A375 cells than reference drug, suggesting their possible lower toxicity and wider therapeutic index. As further study revealed, selected compounds inhibited tubulin polymerization via colchicine binding site in dose dependent manner, leading to aberrant mitotic spindle formation, cell cycle arrest and apoptosis. Summarizing, the current study showed that among obtained mitotic-specific inhibitors analogue with thiophene ring showed the highest antiproliferative activity and selectivity against cancer cells.
Collapse
Affiliation(s)
- Magdalena Perużyńska
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland; (Ł.S.); (M.D.); (M.K.)
| | - Aleksandra Borzyszkowska-Ledwig
- Department of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland; (A.B.-L.); (J.G.S.); (Ł.S.); (T.J.I.)
| | - Jacek G. Sośnicki
- Department of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland; (A.B.-L.); (J.G.S.); (Ł.S.); (T.J.I.)
| | - Łukasz Struk
- Department of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland; (A.B.-L.); (J.G.S.); (Ł.S.); (T.J.I.)
| | - Tomasz J. Idzik
- Department of Organic and Physical Chemistry, Faculty of Chemical Technology and Engineering, West Pomeranian University of Technology, Szczecin, Al. Piastów 42, 71-065 Szczecin, Poland; (A.B.-L.); (J.G.S.); (Ł.S.); (T.J.I.)
| | - Gabriela Maciejewska
- Faculty of Chemistry, Wrocław University of Technology, Wybrzeże Wyspiańskiego 27, 50-370 Wrocław, Poland;
| | - Łukasz Skalski
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland; (Ł.S.); (M.D.); (M.K.)
| | - Katarzyna Piotrowska
- Department of Physiology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland;
| | - Paweł Łukasik
- Department of Medical Chemistry, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland;
| | - Marek Droździk
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland; (Ł.S.); (M.D.); (M.K.)
| | - Mateusz Kurzawski
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111 Szczecin, Poland; (Ł.S.); (M.D.); (M.K.)
| |
Collapse
|
20
|
Cui H, Arnst K, Miller DD, Li W. Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance. Curr Med Chem 2020; 27:6573-6595. [DOI: 10.2174/0929867326666191016113631] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 09/06/2019] [Accepted: 09/12/2019] [Indexed: 12/12/2022]
Abstract
Paclitaxel (PTX) is a first-line drug for late-stage non-small cell lung cancer (NSCLC) patients
who do not benefit from targeted therapy or immunotherapy. However, patients invariably develop
resistance to PTX upon prolonged treatments. Although diverse mechanisms leading to PTX
resistance have been well-documented in the literature, strategies to overcome PTX resistance in
NSCLC based on these mechanisms are still challenging. In this article, we reviewed recent advancements
elucidating major mechanisms of PTX resistance in NSCLC, including the overexpression of
ABC transporters, alternations to tubulin structures, and the involvement of cytokines, miRNAs, kinase
signaling pathways, and epithelial-mesenchymal transition. Potential markers of PTX resistance or
PTX response that could help to direct treatment decisions and restore cellular sensitivity to PTX were
also discussed. Finally, we summarized the corresponding strategies to overcome PTX resistance in
NSCLC cells, which might provide new insights into clinical trials and benefit lung cancer patients in
the future.
Collapse
Affiliation(s)
- Hongmei Cui
- Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States
| | - Kinsie Arnst
- Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States
| | - Duane D. Miller
- Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States
| | - Wei Li
- Department of Pharmaceutical Science, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States
| |
Collapse
|
21
|
Karatoprak GŞ, Küpeli Akkol E, Genç Y, Bardakcı H, Yücel Ç, Sobarzo-Sánchez E. Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications. Molecules 2020; 25:E2560. [PMID: 32486408 PMCID: PMC7321081 DOI: 10.3390/molecules25112560] [Citation(s) in RCA: 56] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 05/25/2020] [Accepted: 05/26/2020] [Indexed: 01/08/2023] Open
Abstract
Combretastatins are a class of closely related stilbenes (combretastatins A), dihydrostilbenes (combretastatins B), phenanthrenes (combretastatins C) and macrocyclic lactones (combretastatins D) found in the bark of Combretum caffrum (Eckl. & Zeyh.) Kuntze, commonly known as the South African bush willow. Some of the compounds in this series have been shown to be among the most potent antitubulin agents known. Due to their structural simplicity many analogs have also been synthesized. Combretastatin A4 phosphate is the most frequently tested compounds in preclinical and clinical trials. It is a water-soluble prodrug that the body can rapidly metabolize to combretastatin A4, which exhibits anti-tumor properties. In addition, in vitro and in vivo studies on combretastatins have determined that these compounds also have antioxidant, anti-inflammatory and antimicrobial effects. Nano-based formulations of natural or synthetic active agents such as combretastatin A4 phosphate exhibit several clear advantages, including improved low water solubility, prolonged circulation, drug targeting properties, enhanced efficiency, as well as fewer side effects. In this review, a synopsis of the recent literature exploring the combretastatins, their potential effects and nanoformulations as lead compounds in clinical applications is provided.
Collapse
Affiliation(s)
- Gökçe Şeker Karatoprak
- Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey;
| | - Esra Küpeli Akkol
- Department of Pharmacognosy Faculty of Pharmacy, Gazi University, 06330 Ankara, Turkey
| | - Yasin Genç
- Department of Pharmacognosy, Faculty of Pharmacy, Hacettepe University, 06100 Sıhhiye, Ankara, Turkey;
| | - Hilal Bardakcı
- Department of Pharmacognosy, Faculty of Pharmacy, Acibadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey;
| | - Çiğdem Yücel
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey;
| | - Eduardo Sobarzo-Sánchez
- Instituto de Investigación e Innovación en Salud, Facultad de Ciencias de la Salud, Universidad Central de Chile, Santiago 8330507, Chile;
- Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| |
Collapse
|
22
|
Rodrigues DA, Guerra FS, Sagrillo FS, de Sena M Pinheiro P, Alves MA, Thota S, Chaves LS, Sant'Anna CMR, Fernandes PD, Fraga CAM. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem 2020; 15:539-551. [PMID: 32022441 DOI: 10.1002/cmdc.201900716] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 01/29/2020] [Indexed: 01/14/2023]
Abstract
Targeting histone deacetylases (HDACs) and phosphatidylinositol 3-kinases (PI3Ks) is a very promising approach for cancer treatment. This manuscript describes the design, synthesis, in vitro pharmacological profile, and molecular modeling of a novel class of N-acylhydrazone (NAH) derivatives that act as HDAC6/8 and PI3Kα dual inhibitors. The surprising selectivity for PI3Kα may be related to differences in the conformation in the active site. Cellular studies showed that these compounds act in HDAC6 inhibition and the PI3/K/AKT/mTOR pathway. The compounds that are selective for inhibition of HDAC6/8 and inhibit PI3Kα show potential for the treatment of cancer.
Collapse
Affiliation(s)
- Daniel A Rodrigues
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil.,Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, 21941-909, Rio de Janeiro, RJ, Brazil
| | - Fabiana S Guerra
- Laboratório de Farmacologia da Dor e da Inflamação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Fernanda S Sagrillo
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Pedro de Sena M Pinheiro
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil.,Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Marina A Alves
- Laboratório de Apoio ao Desenvolvimento Tecnológico (LADETEC), Instituto de Química, Avenida Horácio Macedo, 1281, Polo de Química, Bloco C, Cidade Universitária, 21941-598, Rio de Janeiro, RJ, Brazil
| | - Sreekanth Thota
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Lorrane S Chaves
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil.,Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Carlos M R Sant'Anna
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil.,Departamento de Química, Instituto de Ciências Exatas, Universidade Federal Rural do Rio de Janeiro, 23970-000, Seropédica, RJ, Brazil
| | - Patrícia D Fernandes
- Laboratório de Farmacologia da Dor e da Inflamação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil
| | - Carlos A M Fraga
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, PO Box 68023, 21941-902, Rio de Janeiro, RJ, Brazil.,Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, 21941-909, Rio de Janeiro, RJ, Brazil.,Programa de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 21941-902, Rio de Janeiro, RJ, Brazil
| |
Collapse
|
23
|
Alves MSD, das Neves RN, Sena-Lopes Â, Domingues M, Casaril AM, Segatto NV, Nogueira TCM, de Souza MVN, Savegnago L, Seixas FK, Collares T, Borsuk S. Antiparasitic activity of furanyl N-acylhydrazone derivatives against Trichomonas vaginalis: in vitro and in silico analyses. Parasit Vectors 2020; 13:59. [PMID: 32046788 PMCID: PMC7014680 DOI: 10.1186/s13071-020-3923-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 02/01/2020] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Trichomonas vaginalis is the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5-9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease. METHODS Herein, we report the in vitro and in silico analysis of 12 furanyl N-acylhydrazone derivatives (PFUR 4, a-k) against Trichomonas vaginalis. Trichomonas vaginalis ATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalis activity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells. RESULTS The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50 of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b with T. vaginalis enzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interacted in silico with thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4). CONCLUSIONS Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents for T. vaginalis.
Collapse
Affiliation(s)
- Mirna Samara Dié Alves
- Laboratório de Biotecnologia Infecto-parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Raquel Nascimento das Neves
- Laboratório de Biotecnologia Infecto-parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Ângela Sena-Lopes
- Laboratório de Biotecnologia Infecto-parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Micaela Domingues
- Laboratório de Neurobiotecnologia, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Angela Maria Casaril
- Laboratório de Neurobiotecnologia, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Natália Vieira Segatto
- Laboratório de Biotecnologia do Câncer, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | | | - Marcus Vinicius Nora de Souza
- Instituto de Tecnologia em Fármacos-Far-Manguinhos, Fiocruz-Fundação Oswaldo Cruz, Rio de Janeiro, RJ 21041-250 Brazil
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Cidade Universitária, Rio de Janeiro, RJ 21945-970 Brazil
| | - Lucielli Savegnago
- Laboratório de Neurobiotecnologia, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Fabiana Kömmling Seixas
- Laboratório de Biotecnologia do Câncer, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Tiago Collares
- Laboratório de Biotecnologia do Câncer, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| | - Sibele Borsuk
- Laboratório de Biotecnologia Infecto-parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS 96010-900 Brazil
| |
Collapse
|
24
|
New 2-amino-pyridinyl-N-acylhydrazones: Synthesis and identification of their mechanism of anti-inflammatory action. Biomed Pharmacother 2020; 123:109739. [PMID: 31918210 DOI: 10.1016/j.biopha.2019.109739] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 12/06/2019] [Accepted: 12/08/2019] [Indexed: 12/18/2022] Open
Abstract
AIMS The main aim of this paper was the synthesis and the evaluation of the anti-inflammatory activity of LASSBio-1828 (an amino-pyridinyl-N-acylhydrazone) and its respective hydrochloride, based on a p38α MAPK inhibitor (LASSBio-1824) previously synthesized by our group. MAIN METHODS The compounds were tested regarding their cell viability effect and on acute models of inflammation such as formalin-induced licking test, cell migration and inflammatory mediators quantification. KEY FINDINGS Treatment with the compounds inhibited p38α, reduced inflammatory pain, cell migration and inflammatory mediators that participate on the MAPK pathway such as TNF-α and IL-1β. SIGNIFICANCE Taken together, these results suggest that the synthesis of the corresponding hydrochloride of LASSBio-1828 enhanced its potency as a p38 inhibitor, and also that this compound could be considered a good anti-inflammatory drug candidate after further studies.
Collapse
|
25
|
Anti-inflammatory activity of SintMed65, an N-acylhydrazone derivative, in a mouse model of allergic airway inflammation. Int Immunopharmacol 2019; 75:105735. [PMID: 31306982 DOI: 10.1016/j.intimp.2019.105735] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 06/17/2019] [Accepted: 06/29/2019] [Indexed: 12/11/2022]
Abstract
Asthma is a chronic, complex and heterogeneous inflammatory illness, characterized by obstruction of the lower airways. About 334 million people worldwide suffer from asthma, and these estimates, as well as the severity of the disease, have increased in the last decades. Glucocorticoids are currently the most widely used drugs in the treatment and control of asthma symptoms, but their prolonged use can cause serious adverse effects. N-acylhydrazone derivatives have been tested in pre-clinical studies in models of inflammatory diseases. Here we tested SintMed65 (N'-[(1E)-3-(4-nitrophenylhydrazono)]-(2E)-propan-2-ylidene-3,5-dinitrobenzohydrazide), a compound belonging to a novel class of immunosuppressive drugs, in a mouse model of allergic airway inflammation. BALB/c mice were sensitized previously and challenged with ovalbumin for five consecutive days and SintMed65 treatment was performed orally 1 h prior to challenge with ovalbumin. Administration of SintMed65, as well as the reference drug dexamethasone, reduced cellularity and the number of eosinophils in the bronchoalveolar fluid (BALF). SintMed65 also reduced the production of Th2 cytokines IL-4, IL-5 and IL-13 in the BALF, and IL-4, IL-10 and CCL8 gene expression in lung, compared to vehicle-treated mice. Importantly, a reduction in the number of leukocytes and in the mucus production in lungs of SintMed65-treated mice was found, compared to the vehicle-treated group. In contrast, IgE production was not significantly altered after treatment with SintMed65. Our results demonstrate that compound SintMed65 possesses anti-inflammatory characteristics, suggesting its therapeutic potential for the treatment of allergic diseases.
Collapse
|
26
|
Sun F, Yin T, Feng A, Hu Y, Yu C, Li T, Yao C. Base-promoted regiodivergent allylation of N-acylhydrazones with Morita–Baylis–Hillman carbonates by tuning the catalyst. Org Biomol Chem 2019; 17:5283-5293. [DOI: 10.1039/c9ob00194h] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A catalyst-controlled regiodivergent allylation reaction of N-acylhydrazones (NAHs) with Morita–Baylis–Hillman (MBH) carbonates has been developed, paving a new avenue for the diversification of NAH.
Collapse
Affiliation(s)
- Fang Sun
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Tingrui Yin
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Anni Feng
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Yong Hu
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Chenxia Yu
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Tuanjie Li
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| | - Changsheng Yao
- School of Chemistry and Materials Science
- Jiangsu Key Lab of Green Synthetic Chemistry for Functional Materials. Jiangsu Normal University
- Xuzhou
- P R China
| |
Collapse
|
27
|
Paier CRK, Maranhão SS, Carneiro TR, Lima LM, Rocha DD, da Silva Santos R, de Farias KM, de Moraes-Filho MO, Pessoa C. Natural products as new antimitotic compounds for anticancer drug development. Clinics (Sao Paulo) 2018; 73:e813s. [PMID: 30540125 PMCID: PMC6256996 DOI: 10.6061/clinics/2018/e813s] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 10/09/2018] [Indexed: 12/19/2022] Open
Abstract
Cell cycle control genes are frequently mutated in cancer cells, which usually display higher rates of proliferation than normal cells. Dysregulated mitosis leads to genomic instability, which contributes to tumor progression and aggressiveness. Many drugs that disrupt mitosis have been studied because they induce cell cycle arrest and tumor cell death. These antitumor compounds are referred to as antimitotics. Vinca alkaloids and taxanes are natural products that target microtubules and inhibit mitosis, and their derivatives are among the most commonly used drugs in cancer therapy worldwide. However, severe adverse effects such as neuropathies are frequently observed during treatment with microtubule-targeting agents. Many efforts have been directed at developing improved antimitotics with increased specificity and decreased likelihood of inducing side effects. These new drugs generally target specific components of mitotic regulation that are mainly or exclusively expressed during cell division, such as kinases, motor proteins and multiprotein complexes. Such small molecules are now in preclinical studies and clinical trials, and many are products or derivatives from natural sources. In this review, we focused on the most promising targets for the development of antimitotics and discussed the advantages and disadvantages of these targets. We also highlighted the novel natural antimitotic agents under investigation by our research group, including combretastatins, withanolides and pterocarpans, which show the potential to circumvent the main issues in antimitotic therapy.
Collapse
Affiliation(s)
- Carlos Roberto Koscky Paier
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- *Corresponding author. E-mail:
| | - Sarah Sant'Anna Maranhão
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Teiliane Rodrigues Carneiro
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
- Laboratorio de Avaliacao e Sintese de Substancias Bioativas (LASSBio), Instituto de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR
| | - Lídia Moreira Lima
- Laboratorio de Avaliacao e Sintese de Substancias Bioativas (LASSBio), Instituto de Ciencia e Tecnologia de Farmacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, BR
| | - Danilo Damasceno Rocha
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Renan da Silva Santos
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Kaio Moraes de Farias
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Manoel Odorico de Moraes-Filho
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| | - Claudia Pessoa
- Laboratorio de Oncologia Experimental, Nucleo de Pesquisa e Desenvolvimento de Medicamentos (NPDM), Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Farmacologia, Universidade Federal do Ceara, Fortaleza, CE, BR
- Programa de Pos graduacao em Biotecnologia, Rede Nordeste de Biotecnologia (RENORBIO), Universidade Federal do Ceara, Fortaleza, CE, BR
| |
Collapse
|
28
|
Guimarães ET, Dos Santos TB, Silva DKC, Meira CS, Moreira DRM, da Silva TF, Salmon D, Barreiro EJ, Soares MBP. Potent immunosuppressive activity of a phosphodiesterase-4 inhibitor N-acylhydrazone in models of lipopolysaccharide-induced shock and delayed-type hypersensitivity reaction. Int Immunopharmacol 2018; 65:108-118. [PMID: 30312879 DOI: 10.1016/j.intimp.2018.09.047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 09/19/2018] [Accepted: 09/28/2018] [Indexed: 12/13/2022]
Abstract
Immunosuppressive drugs are widely used for the treatment of immune-mediated diseases and inflammation, but the toxicity and side effects of the available immunosuppressors make the search of new agents of great relevance. Here, we evaluated the immunomodulatory activity of an N-acylhydrazone derivative, (E)-N'-(3,4-dimethoxybenzylidene)-4-methoxybenzohydrazide (LASSBio-1386), a phosphodiesterase-4 (PDE-4) inhibitor. LASSBio-1386 inhibited lymphocyte activation in a concentration-dependent fashion, decreasing lymphoproliferation and IFN-γ and IL-2 production stimulated by anti-CD3/CD28 mAbs or concanavalin A (Con A) and inducing cell-cycle arrest in the G0/G1 phase. These effects were not blocked by RU486, a glucocorticoid receptor (GR) antagonist, indicating an effect independent of glucocorticoid receptor activation. Combination index-isobologram analysis indicates a synergistic effect between LASSBio-1386 and dexamethasone in lymphoproliferation inhibition. LASSBio-1386 presented immunomodulatory action in macrophage cultures, as observed by a significant and concentration-dependent decrease in NO and TNF-α production, an effect achieved by reducing IĸB expression and NF-κB activation. In the mouse model of endotoxic shock, LASSBio-1386 at 50 and 100 mg/kg protected 50 and 85% of mice against LPS-induced lethality, respectively. In agreement to its in vitro action, treatment with 100 mg/kg of LASSBio-1386 reduced TNF-α and IL-1β serum levels, while increased IL-6 and IL-10. Finally, LASSBio-1386 reduced the paw edema in a BSA-induced delayed-type hypersensitivity model. These findings demonstrate the immunomodulatory and immunosuppressant effects of LASSBio-1386 and indicate this molecule is a promising pharmacologic agent for immune-mediated diseases.
Collapse
Affiliation(s)
- Elisalva Teixeira Guimarães
- Núcleo de Estudo e Pesquisa em Histopatologia, Departamento de Ciências da Vida, Universidade Estadual da Bahia, CEP 41150-000 Salvador, BA, Brazil; Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), CEP 40296-710 Salvador, BA, Brazil
| | - Tatiana Barbosa Dos Santos
- Núcleo de Estudo e Pesquisa em Histopatologia, Departamento de Ciências da Vida, Universidade Estadual da Bahia, CEP 41150-000 Salvador, BA, Brazil; Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), CEP 40296-710 Salvador, BA, Brazil
| | - Dahara Keyse Carvalho Silva
- Núcleo de Estudo e Pesquisa em Histopatologia, Departamento de Ciências da Vida, Universidade Estadual da Bahia, CEP 41150-000 Salvador, BA, Brazil; Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), CEP 40296-710 Salvador, BA, Brazil
| | - Cássio Santana Meira
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), CEP 40296-710 Salvador, BA, Brazil
| | | | - Tiago Fernandes da Silva
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CEP 21941-971 Rio de Janeiro, RJ, Brazil
| | - Didier Salmon
- Instituto de Bioquímica Médica Leopoldo de Meis, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, CEP 21941-590 Rio de Janeiro, RJ, Brazil
| | - Eliezer J Barreiro
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®), Universidade Federal do Rio de Janeiro, CEP 21941-971 Rio de Janeiro, RJ, Brazil
| | - Milena Botelho Pereira Soares
- Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (FIOCRUZ), CEP 40296-710 Salvador, BA, Brazil; Centro de Biotecnologia e Terapia Celular, Hospital São Rafael, CEP 41253-190 Salvador, BA, Brazil.
| |
Collapse
|
29
|
N-Acylhydrazones as drugs. Bioorg Med Chem Lett 2018; 28:2797-2806. [DOI: 10.1016/j.bmcl.2018.07.015] [Citation(s) in RCA: 87] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2018] [Revised: 07/05/2018] [Accepted: 07/08/2018] [Indexed: 01/09/2023]
|
30
|
Silva JC, de Oliveira Júnior RG, Silva MGE, de Lavor ÉM, Soares JMD, de Lima-Saraiva SRG, Diniz TC, Mendes RL, de Alencar Filho EB, Barreiro EJDL, Lima LM, Almeida JRGDS. LASSBio-1586, an N-acylhydrazone derivative, attenuates nociceptive behavior and the inflammatory response in mice. PLoS One 2018; 13:e0199009. [PMID: 30059558 PMCID: PMC6066216 DOI: 10.1371/journal.pone.0199009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Accepted: 05/24/2018] [Indexed: 12/14/2022] Open
Abstract
Pain and inflammation are complex clinical conditions that are present in a wide variety of disorders. Most drugs used to treat pain and inflammation have potential side effects, which makes it necessary to search for new sources of bioactive molecules. In this paper, we describe the ability of LASSBio-1586, an N-acylhydrazone derivative, to attenuate nociceptive behavior and the inflammatory response in mice. Antinociceptive activity was evaluated through acetic acid-induced writhing and formalin-induced nociception tests. In these experimental models, LASSBio-1586 significantly (p<0.05) reduced nociceptive behavior. Several methods of acute and chronic inflammation induced by different chemical (carrageenan, histamine, croton oil, arachidonic acid) and physical (cotton pellet) agents were used to evaluate the anti-inflammatory effect of LASSBio-1586. LASSBio-1586 exhibited potent anti-inflammatory activity in all tests (p<0.05). Study of the mechanism of action demonstrated the possible involvement of the nitrergic, serotonergic and histamine signaling pathways. In addition, a molecular docking study was performed, indicating that LASSBio-1586 is able to block the COX-2 enzyme, reducing arachidonic acid metabolism and consequently decreasing the production of prostaglandins, which are important inflammatory mediators. In summary, LASSBio-1586 exhibited relevant antinociceptive and anti-inflammatory potential and acted on several targets, making it a candidate for a new multi-target oral anti-inflammatory drug.
Collapse
Affiliation(s)
- Juliane Cabral Silva
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
| | | | - Mariana Gama e Silva
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
| | - Érica Martins de Lavor
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
| | - Juliana Mikaelly Dias Soares
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
| | | | - Tâmara Coimbra Diniz
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
| | | | | | - Eliezer Jesus de Lacerda Barreiro
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Rio de Janeiro, Brasil
| | - Lídia Moreira Lima
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Rio de Janeiro, Brasil
| | - Jackson Roberto Guedes da Silva Almeida
- Núcleo de Estudos e Pesquisas de Plantas Medicinais (NEPLAME), Universidade Federal do Vale do São Francisco, Petrolina, Brasil
- Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Rio de Janeiro, Brasil
- * E-mail:
| |
Collapse
|
31
|
Korcz M, Sączewski F, Bednarski PJ, Kornicka A. Synthesis, Structure, Chemical Stability, and In Vitro Cytotoxic Properties of Novel Quinoline-3-Carbaldehyde Hydrazones Bearing a 1,2,4-Triazole or Benzotriazole Moiety. Molecules 2018; 23:E1497. [PMID: 29925826 PMCID: PMC6100353 DOI: 10.3390/molecules23061497] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Revised: 06/15/2018] [Accepted: 06/16/2018] [Indexed: 11/23/2022] Open
Abstract
A small library of novel quinoline-3-carbaldehyde hydrazones (Series 1), acylhydrazones (Series 2), and arylsulfonylhydrazones (Series 3) bearing either a 1,2,4-triazole or benzotriazole ring at position 2 was prepared, characterized by elemental analyses and IR, NMR, and MS spectra, and then subjected to in vitro cytotoxicity studies on three human tumor cell lines: DAN-G, LCLC-103H, and SISO. In general, compounds 4, 6, and 8 substituted with a 1,2,4-triazole ring proved to be inactive, whereas the benzotriazole-containing quinolines 5, 7, and 9 elicited pronounced cancer cell growth inhibitory effects with IC50 values in the range of 1.23⁻7.39 µM. The most potent 2-(1H-benzotriazol-1-yl)-3-[2-(pyridin-2-yl)hydrazonomethyl]quinoline (5e) showed a cytostatic effect on the cancer cell lines, whereas N′-[(2-(1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-benzohydrazide (7a) and N′-[(2-1H-benzotriazol-1-yl)quinolin-3-yl)methylene]-naphthalene-2-sulfonohydrazide (9h) exhibited selective activity against the pancreas cancer DAN-G and cervical cancer SISO cell lines. Based on the determined IC50 values, the compound 5e seems to be leading compound for further development as anticancer agent.
Collapse
Affiliation(s)
- Martyna Korcz
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | - Franciszek Sączewski
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | - Patrick J Bednarski
- Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, F.-L. Jahn Strasse 17, D-17489 Greifswald, Germany.
| | - Anita Kornicka
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| |
Collapse
|
32
|
Corradi S, Mazzoccanti G, Ghirga F, Quaglio D, Nevola L, Massera C, Ugozzoli F, Giannini G, Ciogli A, D’Acquarica I. Synthesis of Bromoundecyl Resorc[4]arenes and Applications of the Cone Stereoisomer as Selector for Liquid Chromatography. J Org Chem 2018; 83:7683-7693. [DOI: 10.1021/acs.joc.8b00488] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Silvia Corradi
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
| | - Giulia Mazzoccanti
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
| | - Francesca Ghirga
- Center For Life Nano Science@Sapienza, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00161 Roma, Italy
| | - Deborah Quaglio
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
| | - Laura Nevola
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
- IDP Discovery Pharma, 08028 Barcelona, Spain
| | - Chiara Massera
- Dipartimento di Scienze Chimiche, della Vita e della Sostenibilità Ambientale, Università di Parma and INSTM UdR Parma, Parco Area delle Scienze 17/A, 43124 Parma, Italy
| | - Franco Ugozzoli
- Dipartimento di Ingegneria e Architettura, Università di Parma, Parco Area delle Scienze 181/A, 43124 Parma, Italy
| | - Giuseppe Giannini
- Corporate R&D, Alfasigma S.p.A., Via Pontina km 30,400, 00071 Pomezia, Italy
| | - Alessia Ciogli
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
| | - Ilaria D’Acquarica
- Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, P.le A. Moro 5, 00185 Roma, Italy
| |
Collapse
|
33
|
Santos AF, Ferreira IP, Takahashi JA, Rodrigues GLS, Pinheiro CB, Teixeira LR, Rocha WR, Beraldo H. Silver(i) complexes with 2-acetylpyridinebenzoylhydrazones exhibit antimicrobial effects against yeast and filamentous fungi. NEW J CHEM 2018. [DOI: 10.1039/c7nj04280a] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
2-Acetylpyridinebenzoylhydrazones and their silver(i) complexes show antimicrobial effects and deserve to be investigated as antifungal drug candidates.
Collapse
Affiliation(s)
- Ane F. Santos
- Departamento de Química
- Universidade Federal de Minas Gerais
- Belo Horizonte
- Brazil
| | | | | | | | - Carlos B. Pinheiro
- Departamento de Física
- Universidade Federal de Minas Gerais
- Belo Horizonte
- Brazil
| | - Letícia R. Teixeira
- Departamento de Química
- Universidade Federal de Minas Gerais
- Belo Horizonte
- Brazil
| | - Willian R. Rocha
- Departamento de Química
- Universidade Federal de Minas Gerais
- Belo Horizonte
- Brazil
| | - Heloisa Beraldo
- Departamento de Química
- Universidade Federal de Minas Gerais
- Belo Horizonte
- Brazil
| |
Collapse
|
34
|
Cao YN, Zheng LL, Wang D, Liang XX, Gao F, Zhou XL. Recent advances in microtubule-stabilizing agents. Eur J Med Chem 2017; 143:806-828. [PMID: 29223097 DOI: 10.1016/j.ejmech.2017.11.062] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 11/04/2017] [Accepted: 11/22/2017] [Indexed: 10/18/2022]
Abstract
Highly dynamic mitotic spindle microtubules are superb therapeutic targets for a group of chemically diverse and clinically successful anticancer drugs. Microtubule-targeted drugs disrupt microtubule dynamics in distinct ways, and they are primarily classified into two groups: microtubule destabilizing agents (MDAs), such as vinblastine, colchicine, and combretastatin-A4, and microtubule stabilizing agents (MSAs), such as paclitaxel and epothilones. Systematic discovery and development of new MSAs have been aided by extensive research on paclitaxel, yielding a large number of promising anticancer compounds. This review focuses on the natural sources, structural features, mechanisms of action, structure-activity relationship (SAR) and chemical synthesis of MSAs. These MSAs mainly include paclitaxel, taccalonolides, epothilones, FR182877 (cyclostreptin), dictyostatin, discodermolide, eleutherobin and sarcodictyins, zampanolide, dactylolide, laulimalides, peloruside and ceratamines from natural sources, as well as small molecular microtubule stabilizers obtained via chemical synthesis. Then we discuss the application prospect and development of these anticancer compounds.
Collapse
Affiliation(s)
- Ya-Nan Cao
- Agronomy College, Sichuan Agriculture University, Chengdu 611130, PR China; School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, PR China
| | - Ling-Li Zheng
- Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610500, PR China
| | - Dan Wang
- Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Qld 4072, Australia
| | - Xiao-Xia Liang
- Agronomy College, Sichuan Agriculture University, Chengdu 611130, PR China.
| | - Feng Gao
- Agronomy College, Sichuan Agriculture University, Chengdu 611130, PR China; School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, PR China.
| | - Xian-Li Zhou
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, PR China
| |
Collapse
|
35
|
Structural characterization and cytotoxicity studies of different forms of a combretastatin A4 analogue. J Mol Struct 2017. [DOI: 10.1016/j.molstruc.2017.06.093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Seddigi ZS, Malik MS, Saraswati AP, Ahmed SA, Babalghith AO, Lamfon HA, Kamal A. Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. MEDCHEMCOMM 2017; 8:1592-1603. [PMID: 30108870 DOI: 10.1039/c7md00227k] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 07/03/2017] [Indexed: 01/01/2023]
Abstract
The dynamic and crucial role of tubulin in different cellular functions rendered it a promising target in anticancer drug development. Combretastatin A-4 (CA-4), an inhibitor of tubulin polymerization isolated from natural sources, is a lead molecule with significant cytotoxicity against tumour cells. Owing to its non polar nature it exhibits low solubility in natural biological fluids, thereby prompting the development of new CA-4 based derivatives. The modification of this lead molecule was mostly carried out by keeping the crucial cis-orientation of the double bond intact, along with a trimethoxyphenyl aromatic ring, by employing different approaches. The issue of solubility was also addressed by the development of water soluble prodrugs of CA-4. The present review highlights the investigations into the parallel development of both new CA-4 based derivatives and prodrugs in the past few years.
Collapse
Affiliation(s)
- Zaki S Seddigi
- Department of Environmental Health , College of Public Health and Health Informatics , Umm Al-Qura University , 21955 Makkah , Saudi Arabia
| | - M Shaheer Malik
- Science and Technology Unit , Umm Al-Qura University , 21955 Makkah , Saudi Arabia
| | - A Prasanth Saraswati
- Department of Medicinal Chemistry and Pharmacology , CSIR - Indian Institute of Chemical Technology , Hyderabad 500 007 , India . ; ; Tel: +91 40 27193157
| | - Saleh A Ahmed
- Department of Chemistry , Faculty of Applied Sciences , Umm Al-Qura University , 21955 Makkah , Saudi Arabia
| | - Ahmed O Babalghith
- Department of Medical Genetics, Faculty of Medicine , Umm Al-Qura University , 21955 Makkah , Saudi Arabia
| | - Hawazen A Lamfon
- Department of Biology , Faculty of Applied Sciences , Umm Al-Qura University , 21955 Makkah , Saudi Arabia
| | - Ahmed Kamal
- Department of Medicinal Chemistry and Pharmacology , CSIR - Indian Institute of Chemical Technology , Hyderabad 500 007 , India . ; ; Tel: +91 40 27193157
| |
Collapse
|
37
|
Solid state characterization and theoretical study of non-linear optical properties of a Fluoro-N-Acylhydrazide derivative. PLoS One 2017; 12:e0175859. [PMID: 28437446 PMCID: PMC5402957 DOI: 10.1371/journal.pone.0175859] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Accepted: 03/31/2017] [Indexed: 11/19/2022] Open
Abstract
In this work we determine the linear and non-linear optical properties of a Fluoro-N-Acylhydrazide derivative (FBHZ), using a combined supermolecule approach and an iterative scheme of electrostatic polarization, where the atoms of neighbouring molecules are represented by point charges. Our results for non-linear optics (NLO) are comparable to those found experimentally, suggesting that FBHZ constitutes an attractive object for future studies and for use as an interesting material for third-order NLO applications. The dynamic electrical properties of FBHZ in different solvent media are reported. Its molecular properties are closely related to supramolecular features; accordingly, we analysed all its crystal structure properties via intermolecular interactions in the solid state, using X-ray crystallography data and Hirshfeld surface (HS), including thermogravimetric analysis (TGA), differential scanning calorimetry (DSC) and hot-stage microscopy (HSM), where the results reveal crystal stability in respect to temperature variation.
Collapse
|
38
|
Sakchaisri K, Kim SO, Hwang J, Soung NK, Lee KH, Choi TW, Lee Y, Park CM, Thimmegowda NR, Lee PY, Shwetha B, Srinivasrao G, Pham TTH, Jang JH, Yum HW, Surh YJ, Lee KS, Park H, Kim SJ, Kwon YT, Ahn JS, Kim BY. Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One 2017; 12:e0173311. [PMID: 28296906 PMCID: PMC5351965 DOI: 10.1371/journal.pone.0173311] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 02/17/2017] [Indexed: 12/15/2022] Open
Abstract
We have identified the small molecule STK899704 as a structurally novel tubulin inhibitor. STK899704 suppressed the proliferation of cancer cell lines from various origins with IC50 values ranging from 0.2 to 1.0 μM. STK899704 prevented the polymerization of purified tubulin in vitro and also depolymerized microtubule in cultured cells leading to mitotic arrest, associated with increased Cdc25C phosphorylation and the accumulation of both cyclin B1 and polo-like kinase 1 (Plk1), and apoptosis. Unlike many anticancer drugs such as Taxol and doxorubicin, STK899704 effectively displayed antiproliferative activity against multidrug-resistant cancer cell lines. The proposed binding mode of STK899704 is at the interface between αβ-tubulin heterodimer overlapping with the colchicine-binding site. Our in vivo carcinogenesis model further showed that STK 899704 is potent in both the prevention and regression of tumors, remarkably reducing the number and volume of skin tumor by STK899704 treatment. Moreover, it was significant to note that the efficacy of STK899704 was surprisingly comparable to 5-fluorouracil, a widely used anticancer therapeutic. Thus, our results demonstrate the potential of STK899704 to be developed as an anticancer chemotherapeutic and an alternative candidate for existing therapies.
Collapse
Affiliation(s)
- Krisada Sakchaisri
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
| | - Sun-Ok Kim
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Joonsung Hwang
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Nak Kyun Soung
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Kyung Ho Lee
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Tae Woong Choi
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Yongjun Lee
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Chan-Mi Park
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Naraganahalli R. Thimmegowda
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Phil Young Lee
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Bettaswamigowda Shwetha
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Ganipisetti Srinivasrao
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Thi Thu Huong Pham
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
- The Key Laboratory of Enzyme & Protein Technology (KLEPT), VNU University of Science, Vietnam National University, Hanoi, Vietnam
| | - Jae-Hyuk Jang
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Hye-Won Yum
- College of Pharmacy, Seoul National University, Seoul, Korea
| | - Young-Joon Surh
- College of Pharmacy, Seoul National University, Seoul, Korea
| | - Kyung S. Lee
- Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Hwangseo Park
- Department of Bioscience and Biotechnology, Sejong University, Seoul, Korea
| | - Seung Jun Kim
- Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
| | - Yong Tae Kwon
- Department of Biomedical Sciences and Protein Metabolism Medical Research Center, College of Medicine, Seoul National University, Seoul, Korea
| | - Jong Seog Ahn
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| | - Bo Yeon Kim
- Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Ochang, Cheongwon, Korea
| |
Collapse
|
39
|
Ferreira PMP, Bezerra DP, Silva JDN, da Costa MP, Ferreira JRDO, Alencar NMN, Figueiredo ISTD, Cavalheiro AJ, Machado CML, Chammas R, Alves APNN, Moraes MOD, Pessoa C. Preclinical anticancer effectiveness of a fraction from Casearia sylvestris and its component Casearin X: in vivo and ex vivo methods and microscopy examinations. JOURNAL OF ETHNOPHARMACOLOGY 2016; 186:270-279. [PMID: 27067367 DOI: 10.1016/j.jep.2016.04.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Revised: 04/07/2016] [Accepted: 04/07/2016] [Indexed: 06/05/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Casearia sylvestris (Salicaceae) is found in South America and presents antiulcerogenic, cytotoxic, antimicrobial, anti-inflammatory and antihypertensive activities. AIM OF THE STUDY To assess the in vivo and ex vivo antitumor action of a fraction with casearins (FC) and its main component - Casearin X-isolated from C. sylvestris leaves. MATERIALS AND METHODS Firstly, Sarcoma 180 bearing Swiss mice were treated with FC and Cas X for 7 days. Secondly, BALB/c nude animals received hollow fibers with colon carcinoma (HCT-116) or glioblastoma (SF-295) cells and were treated with FC for 4 days. On 5th day, proliferation was determined by MTT assay. RESULTS FC 10 and 25mg/kg/day i.p. and 50mg/kg/day oral and Cas X 25mg/kg/day i.p. and 50mg/kg/day oral revealed tumor growth inhibition rates of 35.8, 86.2, 53.7, 90.0 and 65.5% and such tumors demonstrated rare mitoses and coagulation necrosis areas. Similarly, FC reduced multiplying of HCT-116 and SF-295 cells when evaluated by the Hollow Fiber Assay (2.5 and 5mg/kg/day i.p. and 25 and 50mg/kg/day oral), with cell growth inhibition rates ranging from 33.3 to 67.4% (p<0.05). Flow cytometry experiments revealed that FC reduced membrane integrity and induced DNA fragmentation and mitochondrial depolarization (p<0.05). CONCLUSIONS FC and Cas X were efficient antitumor substances against murine and human cancer cells and caused reversible morphological changes in liver, kidneys and spleens, emphasizing clerodane diterpenes as an emerging class of anticancer molecules.
Collapse
Affiliation(s)
- Paulo Michel Pinheiro Ferreira
- Laboratory in Experimental Cancerology, Department of Biophysics and Physiology, Federal University of Piauí, Teresina, Brazil; Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil; Postgraduate Program in Biotechnology, Federal University of Piauí, Teresina, Brazil.
| | | | | | - Marcília Pinheiro da Costa
- Postgraduate Program in Pharmaceutical Sciences, Federal University of Piauí, Teresina, Brazil; Department of Pharmacy, Federal University of Piauí, Teresina, Brazil
| | | | - Nylane Maria Nunes Alencar
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil
| | | | | | - Camila Maria Longo Machado
- Radioisotopes Research Laboratory, Center for Medical Nuclear, State University of São Paulo, São Paulo, Brazil
| | - Roger Chammas
- Department of Radiology, Faculty of Medicine, State University of São Paulo, São Paulo, Brazil
| | | | - Manoel Odorico de Moraes
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil
| | - Claudia Pessoa
- Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil; Oswaldo Cruz Foundation, Fortaleza, Brazil
| |
Collapse
|
40
|
Cordeiro NM, Freitas RHCN, Fraga CAM, Fernandes PD. Discovery of Novel Orally Active Tetrahydro-Naphthyl-N-Acylhydrazones with In Vivo Anti-TNF-α Effect and Remarkable Anti-Inflammatory Properties. PLoS One 2016; 11:e0156271. [PMID: 27227468 PMCID: PMC4881893 DOI: 10.1371/journal.pone.0156271] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 05/11/2016] [Indexed: 01/08/2023] Open
Abstract
LASSBio-1524 was designed as inhibitor of the IKK-β (kappa β kinase inhibitor) enzyme, which participates in the activation of the nuclear factor κB (NF-κB) canonical pathway, and its three N-acylhydrazone new analogues, LASSBio-1760, LASSBio-1763 and LASSBio-1764 are now being tested on their anti-inflammatory potential. The activity of these compounds was evaluated with the subcutaneous air pouch induced by carrageenan and by subsequent measurement of tumor necrosis factor-α (TNF-α), nitric oxide (NO) and reactive oxygen species (ROS). In the acute inflammation model, the oral pretreatment with doses from 0.3 to 30 mg/kg of N-acylhydrazone derivatives was able to significantly reduce leukocyte migration to the cavity. Pretreatment with LASSBio-1524 and its analogues also decreased NO, TNF-α and ROS biosynthesis an events closely involved with NF-kB pathway. The tetrahydronaphthyl-N-acylhydrazone derivative LASSBio-1764 was the most promising compound from this series, surpassing even LASSBio-1524. Additionally, none of the compounds demonstrated myelotoxicity or cytotoxicity. Cell viability was assayed and these compounds demonstrated to be safe at different concentrations. Western blot analysis demonstrated that LASSBio-1524 and LASSBio-1760 inhibited NF-κB expression in RAW 264.7 cell lineage. Our data indicate that the tested compounds have anti-inflammatory activity, which may be related to inhibition of leukocyte migration, reducing the production of NO, TNF-α and ROS. LASSBio-1524 and LASSBio-1760, in addition to these features, also reduced p65 nuclear expression assessed by western blot in RAW 264.7 murine cells.
Collapse
Affiliation(s)
- Natália M. Cordeiro
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Laboratory of Pharmacology of Pain and Inflammation, Rio de Janeiro, Brazil
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Graduate Programm in Pharmacology and Medicinal Chemistry, Rio de Janeiro, Brazil
| | - Rosana H. C. N. Freitas
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Rio de Janeiro, Brazil
- Federal University of Rio de Janeiro, Chemistry Institute, Graduate Programm in Chemistry, Rio de Janeiro, Brazil
| | - Carlos A. M. Fraga
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Graduate Programm in Pharmacology and Medicinal Chemistry, Rio de Janeiro, Brazil
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), Rio de Janeiro, Brazil
- Federal University of Rio de Janeiro, Chemistry Institute, Graduate Programm in Chemistry, Rio de Janeiro, Brazil
| | - Patricia D. Fernandes
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Laboratory of Pharmacology of Pain and Inflammation, Rio de Janeiro, Brazil
- Federal University of Rio de Janeiro, Institute of Biomedical Science, Graduate Programm in Pharmacology and Medicinal Chemistry, Rio de Janeiro, Brazil
- * E-mail:
| |
Collapse
|
41
|
Rodrigues DA, Ferreira-Silva GÀ, Ferreira ACS, Fernandes RA, Kwee JK, Sant'Anna CMR, Ionta M, Fraga CAM. Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. J Med Chem 2016; 59:655-70. [PMID: 26705137 DOI: 10.1021/acs.jmedchem.5b01525] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
This manuscript describes a novel class of N-acylhydrazone (NAH) derivatives that act as histone deacetylase (HDAC) 6/8 dual inhibitors and were designed from the structure of trichostatin A (1). Para-substituted phenyl-hydroxamic acids presented a more potent inhibition of HDAC6/8 than their meta analogs. In addition, the effect of compounds (E)-4-((2-(4-(dimethylamino)benzoyl)hydrazono)methyl)-N-hydroxybenzamide (3c) and (E)-4-((2-(4-(dimethylamino)benzoyl)-2-methylhydrazono)methyl)-N-hydroxybenzamide (3f) on the acetylation of α-tubulin revealed an increased level of acetylation. These two compounds also affected cell migration, indicating their inhibition of HDAC6. An analysis of the antiproliferative activity of these compounds, which presented the most potent activity, showed that compound 3c induced cell cycle arrest and 3g induced apoptosis through caspase 3/7 activation. These results suggest HDAC6/8 as a potential target of future molecular therapies for cancer.
Collapse
Affiliation(s)
| | - Guilherme À Ferreira-Silva
- Laboratório de Biologia Animal Integrativa, Departamento de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal de Alfenas , 37130-000 Alfenas, Minas Gerais, Brazil
| | - Ana C S Ferreira
- Coordenação de Pesquisa, Instituto Nacional de Câncer , 20231-050 Rio de Janeiro, Rio de Janeiro, Brazil
| | - Renan A Fernandes
- Coordenação de Pesquisa, Instituto Nacional de Câncer , 20231-050 Rio de Janeiro, Rio de Janeiro, Brazil
| | - Jolie K Kwee
- Coordenação de Pesquisa, Instituto Nacional de Câncer , 20231-050 Rio de Janeiro, Rio de Janeiro, Brazil
| | - Carlos M R Sant'Anna
- Departamento de Química, Instituto de Ciências Exatas, Universidade Federal Rural do Rio de Janeiro , 23970-000 Seropédica, Rio de Janeiro, Brazil
| | - Marisa Ionta
- Laboratório de Biologia Animal Integrativa, Departamento de Biologia Celular e do Desenvolvimento, Instituto de Ciências Biomédicas, Universidade Federal de Alfenas , 37130-000 Alfenas, Minas Gerais, Brazil
| | | |
Collapse
|
42
|
Costa FN, Ibiapino AL, de Figueiredo LP, Barreiro EJ, Lima LM, do Amaral DN, de Castro CE, Giacomelli FC, Ferreira FF. Preliminary evaluation of the encapsulation of new antidiabetic sulphonylhydrazone and antitumor N-acylhydrazone derivatives using PLGA nanoparticles. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/1742-6596/617/1/012015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
43
|
N-(1'-naphthyl)-3,4,5-trimethoxybenzohydrazide as microtubule destabilizer: Synthesis, cytotoxicity, inhibition of cell migration and in vivo activity against acute lymphoblastic leukemia. Eur J Med Chem 2015; 96:504-18. [PMID: 25951294 DOI: 10.1016/j.ejmech.2015.02.041] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Revised: 02/20/2015] [Accepted: 02/21/2015] [Indexed: 11/20/2022]
Abstract
Tubulin-interacting agents, like vinca alkaloid and taxanes, play a fundamental role in cancer chemotherapy, making cellular microtubules (MT), one of the few validated anticancer targets. Cancer resistance to classical MT inhibitors has motivated the development of novel molecules with increased efficacy and lower toxicity. Aiming at designing structurally-simple inhibitors of MT assembly, we synthesized a series of thirty-one 3,4,5-trimethoxy-hydrazones and twenty-five derivatives or analogs. Docking simulations suggested that a representative N-acylhydrazone could adopt an appropriate stereochemistry inside the colchicine-binding domain of tubulin. Several of these compounds showed anti-leukemia effects in the nanomolar concentration range. Interference with MT polymerization was validated by the compounds' ability to inhibit MT assembly at the biochemical and cellular level. Selective toxicity investigations done with the most potent compound, a 3,4,5-trimethoxy-hydrazone with a 1-naphthyl group, showed remarkably selective toxicity against leukemia cells in comparison with stimulated normal lymphocytes, and no acute toxicity in vivo. Finally, this molecule was as active as vincristine in a murine model of human acute lymphoblastic leukemia at a weekly dose of 1 mg/kg.
Collapse
|
44
|
da Silva TF, Bispo Júnior W, Alexandre-Moreira MS, Costa FN, Monteiro CEDS, Furlan Ferreira F, Barroso RCR, Noël F, Sudo RT, Zapata-Sudo G, Lima LM, Barreiro EJ. Novel orally active analgesic and anti-inflammatory cyclohexyl-N-acylhydrazone derivatives. Molecules 2015; 20:3067-88. [PMID: 25685912 PMCID: PMC6272651 DOI: 10.3390/molecules20023067] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 02/03/2015] [Indexed: 01/14/2023] Open
Abstract
The N-acylhydrazone (NAH) moiety is considered a privileged structure, being present in many compounds with diverse pharmacological activities. Among the activities attributed to NAH derivatives anti-inflammatory and analgesic ones are recurrent. As part of a research program aiming at the design of new analgesic and anti-inflammatory lead-candidates, a series of cyclohexyl-N-acylhydrazones 10–26 were structurally designed from molecular modification on the prototype LASSBio-294, representing a new class of cycloalkyl analogues. Compounds 10–26 and their conformationally restricted analogue 9 were synthetized and evaluated as analgesic and anti-inflammatory agents in classical pharmacologic protocols. The cyclohexyl-N-acylhydrazones 10–26 and the cyclohexenyl analogue 9 showed great anti-inflammatory and/or analgesic activities, but compound 13 stood out as a new prototype to treat acute and chronic painful states due to its important analgesic activity in a neuropathic pain model.
Collapse
Affiliation(s)
- Tiago Fernandes da Silva
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, P.O. Box 68024, Rio de Janeiro-RJ 21941-971, Brazil; E-Mail:
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-909, Brazil
| | - Walfrido Bispo Júnior
- LaFI—Laboratório de Farmacologia e Imunidade, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas, Maceió-AL 57072-900, Brazil; E-Mails: (W.B.J.); (M.S.A.-M.)
| | - Magna Suzana Alexandre-Moreira
- LaFI—Laboratório de Farmacologia e Imunidade, Instituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas, Maceió-AL 57072-900, Brazil; E-Mails: (W.B.J.); (M.S.A.-M.)
| | - Fanny Nascimento Costa
- Centro de Ciências Naturais e Humanas (CCNH), Universidade Federal do ABC (UFABC) Av. dos Estados 5001, Santo André-SP 09210-580, Brazil; E-Mails: (F.N.C.); (F.F.F.)
- Physics Institute, UERJ, Rio de Janeiro-RJ 20550-900, Brazil; E-Mail:
| | - Carlos Eduardo da Silva Monteiro
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
| | - Fabio Furlan Ferreira
- Centro de Ciências Naturais e Humanas (CCNH), Universidade Federal do ABC (UFABC) Av. dos Estados 5001, Santo André-SP 09210-580, Brazil; E-Mails: (F.N.C.); (F.F.F.)
| | | | - François Noël
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
| | - Roberto Takashi Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
| | - Gisele Zapata-Sudo
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
| | - Lídia Moreira Lima
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, P.O. Box 68024, Rio de Janeiro-RJ 21941-971, Brazil; E-Mail:
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-909, Brazil
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
- Authors to whom correspondence should be addressed; E-Mails: (L.M.L.); (E.J.B.); Tel.: +55-021-3938-6503 (L.M.L.); Tel./Fax: +55-021-3938-6478 (E.J.B.)
| | - Eliezer J. Barreiro
- Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos (INCT-INOFAR), Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, P.O. Box 68024, Rio de Janeiro-RJ 21941-971, Brazil; E-Mail:
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-909, Brazil
- Programa de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro-RJ 21941-902, Brazil; E-Mails: (C.E.S.M.); (F.N.); (R.T.S.); (G.Z.-S.)
- Authors to whom correspondence should be addressed; E-Mails: (L.M.L.); (E.J.B.); Tel.: +55-021-3938-6503 (L.M.L.); Tel./Fax: +55-021-3938-6478 (E.J.B.)
| |
Collapse
|
45
|
McNulty J, van den Berg S, Ma D, Tarade D, Joshi S, Church J, Pandey S. Antimitotic activity of structurally simplified biaryl analogs of the anticancer agents colchicine and combretastatin A4. Bioorg Med Chem Lett 2015; 25:117-21. [DOI: 10.1016/j.bmcl.2014.10.090] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Revised: 10/24/2014] [Accepted: 10/28/2014] [Indexed: 11/29/2022]
|
46
|
|